Piroximone (BioDeep_00000706777)

   


代谢物信息卡片


Piroximone

化学式: C11H11N3O2 (217.0851226)
中文名称: 匹罗昔酮
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC1=C(NC(=O)N1)C(=O)C2=CC=NC=C2
InChI: InChI=1S/C11H11N3O2/c1-2-8-9(14-11(16)13-8)10(15)7-3-5-12-6-4-7/h3-6H,2H2,1H3,(H2,13,14,16)

描述信息

D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors
C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
D020011 - Protective Agents > D002316 - Cardiotonic Agents
D002317 - Cardiovascular Agents

同义名列表

1 个代谢物同义名

Piroximone



数据库引用编号

4 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Jeffrey B Brown, Goo Lee, Gery R Grimm, Terrence A Barrett. Therapeutic benefit of pentostatin in severe IL-10-/- colitis. Inflammatory bowel diseases. 2008 Jul; 14(7):880-7. doi: 10.1002/ibd.20410. [PMID: 18340641]
  • J P Fauvel, N Bernard, M Laville, N Pozet, J Sassard, P Y Zech. Pharmacokinetics of piroximone after oral and intravenous administration to patients with renal insufficiency. British journal of clinical pharmacology. 1995 Feb; 39(2):187-9. doi: 10.1111/j.1365-2125.1995.tb04429.x. [PMID: 7742160]
  • M Berg-Candolfi, B Dulery, F Jehl, K D Haegele. Metabolism and pharmacokinetics of the cardiotonic agent piroximone and of its major metabolite in dog. Xenobiotica; the fate of foreign compounds in biological systems. 1995 Jan; 25(1):59-70. doi: 10.3109/00498259509061833. [PMID: 7604607]
  • H R Ha, F Follath. Determination of piroximone in human plasma by high-performance liquid chromatography. Therapeutic drug monitoring. 1994 Oct; 16(5):499-503. doi: 10.1097/00007691-199410000-00010. [PMID: 7846749]
  • P C Baumann, B J Meyer, M Maggiorini, H R Ha, A Gallino, F Follath. Hemodynamic effects and concentration-effect relationship of a graded infusion of piroximone in patients with severe heart failure. Journal of cardiovascular pharmacology. 1993 Mar; 21(3):489-95. doi: 10.1097/00005344-199303000-00021. [PMID: 7681513]
  • M Berg-Candolfi, J T Borlakoglu, B Dulery, F Jehl, K D Haegele. Assessment of the biotransformation of the cardiotonic agent piroximone by high-performance liquid chromatography and gas chromatography-mass spectrometry. Journal of chromatography. 1992 Feb; 593(1-2):1-7. doi: 10.1016/0021-9673(92)80257-u. [PMID: 1639892]
  • M Buerke, H A Dieterich, J Meyer, H Darius. Synergistic platelet inhibitory effect of the phosphodiesterase inhibitor piroximone and iloprost. Agents and actions. Supplements. 1992; 37(?):71-7. doi: 10.1007/978-3-0348-7262-1_11. [PMID: 1378692]
  • K D Haegele, C Hinze, A M Joder-Ohlenbusch, G Cremer, J Borlak. Effects of a standardized meal on the pharmacokinetics of the new cardiotonic agent piroximone. Arzneimittel-Forschung. 1991 Dec; 41(12):1225-9. doi: NULL. [PMID: 1815521]
  • W E Miller, G T Kennedy, S J Ruberg, R A O'Rourke, M H Crawford. Hemodynamic effects of a constant intravenous infusion of piroximone in patients with severe congestive heart failure. Journal of cardiovascular pharmacology. 1988 Jul; 12(1):72-7. doi: 10.1097/00005344-198807000-00010. [PMID: 2459538]
  • K D Haegele, G G Belz, T T Meinicke, P J Schechter. Pharmacokinetics of piroximone (MDL 19.205) in healthy volunteers. European journal of clinical pharmacology. 1986; 31(2):239-42. doi: 10.1007/bf00606667. [PMID: 3803422]
  • M Petein, T B Levine, J N Cohn. Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure. Journal of the American College of Cardiology. 1984 Aug; 4(2):364-71. doi: 10.1016/s0735-1097(84)80227-2. [PMID: 6736478]
  • F J Keeley, J D Theile, D A Garteiz, D L Weiner, R A Okerholm. Method of analysis of the new cardiotonic agent, MDL 19,205, in plasma and urine and its application in a dog pharmacokinetic study. Journal of chromatography. 1983 Dec; 278(2):379-85. doi: 10.1016/s0378-4347(00)84797-0. [PMID: 6668317]